Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
Pitini
Vincenzo
V
Arrigo
Carmela
C
Altavilla
Giuseppe
G
Naro
Claudia
C
Righi
Maria
M
D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides; D015415:Biomarkers; D004804:Eosinophils / Q000187:drug effects*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D000068877:Imatinib Mesylate; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D039221:mRNA Cleavage and Polyadenylation Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
D001549:Benzamides; D015415:Biomarkers; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha